Efficacy of Immunoglobulin Therapy for Secondary Prevention of Congenital Cytomegalovirus Infection: A Systematic Review and Meta-Analysis
In brief
CMV hyperimmune globulin fails to lower congenital infection rate
A meta-analysis of trials in pregnant women with primary CMV infection found that giving CMV-specific hyperimmune globulin did not significantly reduce vertical transmission, with an overall transmission rate of about 27 percent. The modest trend toward benefit (relative risk 0.73) was not statistically reliable, so routine antenatal immunoglobulin cannot be recommended pending stronger evidence.
- Journal
- Open forum infectious diseases (Q1)
- Published
- 16 July 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Klaudia Gutowska, Anna Kucińska-Chahwan, Marta Bednarek, Anna Jelitto, Radosław Pietrzak, Patrycja Gumuła, et al.
- PMID
- 42500122
- DOI
- 10.1093/ofid/ofag431
Why clinicians should know about it
- Picked for Epidemiology (top studies of the week, 26 July 2026).
- Picked for Oncology and Radiation Oncology (top studies of the week, 26 July 2026): Recent Oncology and Radiation Oncology research from a high-quartile journal
- Picked for Pediatrics and Child Health (top studies of the week, 26 July 2026): Systematic review of immunoglobulin for preventing congenital CMV
- Picked for Infectious Diseases (top studies of the week, 26 July 2026).
Abstract
Congenital cytomegalovirus (cCMV) is the leading infectious cause of long-term neuro-sensory impairment. Aim of meta-analysis was to evaluate the efficacy of antenatal immunoglobulin therapy-particularly cytomegalovirus-specific hyperimmune globulin (HIG)-in preventing vertical transmission and congenital cytomegalovirus infection (cCMV) in pregnancies complicated by primary maternal CMV infection. A search of PubMed, Cochrane Library, Embase, Scopus, ScienceDirect, Taylor & Francis Online, Wiley Online Library, ClinicalTrials.gov, and Google Scholar identified randomized controlled trials, prospective or retrospective cohort studies including pregnant women with serologically confirmed primary CMV infection. Eligible interventions included antenatal CMV-specific or nonspecific immunoglobulins (vs placebo, usual care, historical controls, or no treatment), although all included studies evaluated CMV-specific HIG. Controlled studies showed no significant reduction in transmission (RR 0.73, 95% CI .54-1.00; P = .051) with moderate heterogeneity. The pooled transmission rate after HIG was 27.2%, with substantial heterogeneity. Current evidence does not support routine antenatal immunoglobulin to prevent cCMV.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.